TITLE

A DOUBLE-BLIND EVALUATION OF ANTIHYPERTENSIVE DRUGS

AUTHOR(S)
Grenfell, Raymond F.; Briggs, Arthur H.; Holland, William C.
PUB. DATE
April 1964
SOURCE
Angiology;Apr1964, Vol. 15 Issue 4, p163
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In those patients who received the placebo parenterally, there was a significant decrease in the systolic blood pressure for 139 weeks and in the diastolic blood pressure for 179 weeks when compared with the blood pressure in week 0 of treatment. In those patients who received the hydrogenated alkaloids of ergot parenterally, there was a significant decrease in the systolic blood pressure for 55 weeks and in the diastolic blood pressure for 169 weeks when compared with the blood pressure in week 0 of treatment. When the blood pressure readings of those patients who received the parenteral placebo were compared with the blood pressure readings of those patients who received the drug parenterally, there was no significant difference. The administration of an oral placebo to those whose blood pressure was greater than 200/120 mm Hg before therapy caused a significant decrease in the systolic and diastolic blood pressure in weeks 1 through 24 when compared with the blood pressure of week 0. In those patients receiving guanethidine there was a significant decrease in the systolic and diastolic blood pressure in weeks 1 through 12 when compared with the blood pressure obtained in week 0. However, when the blood pressure was compared with the blood pressure obtained following the administration of oral placebo, there was no significant difference. This, of course, does not suggest that guanethidine is not an effective agent. It is anticipated that at some time in the future the patients receiving the oral placebo will experience an increase in blood pressure to the pretreatment level, whereas those who are receiving guanethidine will continue to maintain a blood pressure lower than that obtained in week 0. Spironolactone caused no significant decrease in the systolic or diastolic blood pressure in any week when compared to the blood pressure obtained following the administration of oral placebo. The administration of spironolactone plus reserpine did cause a significant decrease in systolic blood pressure in all weeks, and in diastolic blood pressure in all weeks except weeks 3, 6 and 12, when compared to the blood pressure obtained following the administration of oral placebo. In those patients who received methysergide, there was a significant decrease in the systolic blood pressure in all weeks except weeks 4, 8, 10 and 12, when compared with the blood pressure obtained following the administration of oral placebo. In the diastolic blood pressure there was a significant decrease in no weeks when the blood pressure was compared to that following oral placebo administration. The data obtained from this study does not suggest that all patients with blood pressure readings comparable to these will respond in a similar fashion with these various agents. However, it does show that if patients are selected at random and treated under carefully controlled conditions such as those employed in this study, comparable results should follow. The study is being continued to determine the maximum duration of the hypotensive effect of placebo given parenterally and ‘high placebo’ given orally. Also, various new agents will be studied as they become available.
ACCESSION #
16371691

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics